Previous 10 | Next 10 |
Interesting insights can be made while looking at broader market performance comparisons. As major trends are slow to change, these insights can be used to find returns into early 2022 and beyond. While some strong points can be made using the data, factors for each individual hol...
Equity markets have performed well in the past 12 months, much to the joy of investors. Maybe that will continue next year or perhaps it won't. But no matter what happens in 2022, it's essential to look beyond the stock market's performance during a single calendar year. The magic formula t...
DexCom is one of the leaders in the diabetes care space with their continuous glucose monitoring device. Advanced technology and convenience of use have propelled their revenue growth upward over the past several years. Their high profit margin indicates an economic moat establish...
Healthcare stock DexCom (NASDAQ: DXCM) has a track record of tremendous business growth and share price appreciation that has remained consistent and robust during the pandemic. In fact, shares are up 50% over the trailing 12 months. In this segment of Backstage Pass , rec...
The diabetes technology market saw some strength in 2021 - and Baird is looking for more of the same in 2022. On the Continuous Glucose Monitoring side, analyst Jeff Johnson says the market stayed strong this year, likely growing in the low- to mid-30% range by users, and just over 30% in dol...
Lone Pine Capital’s 13F portfolio value decreased from $31.03B to $29.68B. The number of positions increased from 36 to 39. They increased Twitter, Workday, and KE Holdings while dropping Global Payments and Mastercard. The top three positions are Shopify, Snap, and DoorDas...
DexCom (DXCM -4.2%) shares have slightly recovered after recording the sharpest intraday loss since late April that followed the submission of a Shelf Registration Statement with the SEC on Monday for issuance of the company’s common stock. With the filing, DexCom (NASDAQ:DXCM) has reg...
The stock market has been on fire in the past year with the S&P 500 climbing more than 30%. And some stocks have actually performed a lot better. Case in point: shares of medical devices specialist DexCom (NASDAQ: DXCM) have soared by 86% in the trailing twelve-month period....
On Nov. 15, institutional investment managers with more than $100 million AUM had to disclose their positions at the end of Q3 2021. I curated a list of some of the best-performing hedge funds and looked into their holdings at the end of September 2021. Several common themes appea...
When it comes to relatively stable healthcare growth stocks, DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) just might fit the bill. Worth around $61 billion, the continuous glucose monitor (CGM) specialist DexCom is small compared to medical device giant Abbott's...
News, Short Squeeze, Breakout and More Instantly...
2024-07-04 10:00:00 ET Growth-oriented investors have experienced a bit of a roller-coaster ride over the past few years. Many companies in the "growth stock" category were struggling just two years ago, but in the bull market we are now experiencing, they're delivering very different resul...
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the...